Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI eye doctor: new tool aims to spot rare retinal diseases

NCT ID NCT06839170

Diagnosis Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an artificial intelligence (AI) system called Retina4IRD that helps doctors diagnose inherited retinal diseases, which are rare eye conditions that can cause vision loss. The AI looks at eye images and patient information to suggest which gene might be causing the disease. Researchers tested it with 295 people and measured how often the AI's top five guesses included the correct gene. The goal is to make diagnosis faster and more accurate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI diagnostic system (FM-IRDs / Retina4IRD)
What this could lead to
If successful, this AI could help doctors diagnose inherited retinal diseases faster and more accurately, potentially improving patient care.
What could go wrong
This is a completed trial, but the AI's accuracy may not be perfect in all cases, and it may not work as well in different populations or real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Feb 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presenting with clinical features suggestive of suspected IRD based on the initial assessment by the physician Exclusion Criteria: * Refusal to undergo WES genetic testing. * Screening for a history of intraocular surgery in both eyes within the past 6 months; * Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc. * Patient data that the investigator deems necessary to exclude.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inherited retinal diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inherited retinal dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inherited retinal diseases

Contacts and locations

Locations

  • Shanghai General Hospital, Shanghai Jiao Tong University

    Shanghai, 200080, China

  • Shanghai general hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.